

D1
Contd
Sub
E1
com.

(iii) applying ultrasonic energy to the patient in an amount sufficient to produce cavitation or rupture of said vesicles, and sufficient to increase the delivery of said bioactive agent from the vasculature into said selected tissue.

D2

164. (Twice amended) A method for enhancing the delivery a bioactive agent to a selected tissue in a patient, said method comprising:

- Sub*
E2
7
- (i) administering said bioactive agent to said patient;
 - (ii) administering an acoustically active composition to said patient, by continuous intravascular infusion; and
 - (iii) applying ultrasonic energy to the patient in an amount sufficient to activate said acoustically active composition, and sufficient to increase the delivery of said bioactive agent to said selected tissue, wherein said ultrasound has a frequency of from about 100 kHz to about 1 MHz.

Please add the following new claim:

D3

--185. (Added) A method according to Claim 116 wherein said ultrasound has a frequency of from about 100 kHz to about 1MHz.--

REMARKS

Reconsideration of the present application in view of the above amendments and following remarks is requested respectfully.

Applicant acknowledges and thanks the Examiner for the withdrawal of the rejection under 35 U.S.C. § 112, second paragraph, and the obviousness-type double patenting rejections over U.S. Patents 6,123,923 and 5,770,222. The remaining rejections are addressed below.